
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


AngioDynamics Inc (ANGO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ANGO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $18.25
1 Year Target Price $18.25
2 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.74% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 411.62M USD | Price to earnings Ratio - | 1Y Target Price 18.25 |
Price to earnings Ratio - | 1Y Target Price 18.25 | ||
Volume (30-day avg) 3 | Beta 0.67 | 52 Weeks Range 5.83 - 13.50 | Updated Date 08/28/2025 |
52 Weeks Range 5.83 - 13.50 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -11.62% | Operating Margin (TTM) -4.53% |
Management Effectiveness
Return on Assets (TTM) -5.03% | Return on Equity (TTM) -17.5% |
Valuation
Trailing PE - | Forward PE 96.15 | Enterprise Value 371861255 | Price to Sales(TTM) 1.41 |
Enterprise Value 371861255 | Price to Sales(TTM) 1.41 | ||
Enterprise Value to Revenue 1.27 | Enterprise Value to EBITDA 213.96 | Shares Outstanding 40633900 | Shares Floating 31380330 |
Shares Outstanding 40633900 | Shares Floating 31380330 | ||
Percent Insiders 6.84 | Percent Institutions 93.84 |
Upturn AI SWOT
AngioDynamics Inc

Company Overview
History and Background
AngioDynamics, Inc. was founded in 1988. It develops, manufactures, and markets a wide range of medical devices used by interventional radiologists, surgeons, and other physicians for vascular access, peripheral vascular disease, and oncology.
Core Business Areas
- Vascular Interventions and Therapies: Focuses on products for peripheral vascular disease, thrombus management, and venous disease. Products include angioplasty balloons, stents, thrombolytic catheters, and venous ablation systems.
- Oncology: Focuses on products for the treatment of liver cancer, kidney cancer, and other cancers. Products include radiofrequency ablation (RFA) systems, microwave ablation (MWA) systems, and irreversible electroporation (IRE) systems.
- Vascular Access: Focuses on products for providing access to the vascular system for infusion therapy, blood sampling, and other procedures. Products include peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and ports.
Leadership and Structure
The leadership team is headed by Jim Clemmer as President and CEO. The organizational structure includes departments for research and development, manufacturing, sales and marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- NanoKnife System (IRE): Irreversible Electroporation technology for ablation of soft tissue tumors. Market share information is not readily available, but competitors include Medtronic, Boston Scientific, and Johnson & Johnson in the ablation space. Revenue is not broken out specifically but is part of the Oncology division.
- BioFlo PICCs: Peripherally inserted central catheters with BioFlo technology designed to resist thrombus accumulation. Market share information for specific PICC brands is not publicly available. Competitors include Becton Dickinson (BD) and Teleflex.
- AngioVac System: A mechanical thrombectomy system designed to remove thrombi or emboli from large vessels. Competitors include Penumbra and Inari Medical.
Market Dynamics
Industry Overview
The medical device industry is characterized by technological advancements, increasing regulatory scrutiny, and consolidation. Demand is driven by an aging population and increasing prevalence of chronic diseases.
Positioning
AngioDynamics holds a niche position, focusing on specific areas within interventional radiology and vascular surgery. They compete with larger players in certain markets but also have unique product offerings.
Total Addressable Market (TAM)
The global medical device market is estimated to be hundreds of billions of dollars. AngioDynamics participates in specific segments within vascular access, peripheral vascular intervention, and oncology. Their positioning allows them to address a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary technologies like NanoKnife
- Established distribution network
- Focus on niche markets
- Experienced management team
Weaknesses
- Smaller market capitalization compared to major competitors
- Reliance on a limited number of key products
- Vulnerable to changes in reimbursement policies
- Product recalls can significantly impact the company.
Opportunities
- Expanding product portfolio through acquisitions
- Growing demand for minimally invasive procedures
- Entering new geographic markets
- Strategic partnerships with other medical device companies
Threats
- Intense competition from larger companies
- Technological obsolescence
- Increasing regulatory hurdles
- Economic downturns affecting hospital budgets
Competitors and Market Share
Key Competitors
- MDT
- BSX
- JNJ
- BDX
- TFX
- INMD
Competitive Landscape
AngioDynamics competes with larger, more established companies. Their strengths lie in niche markets and proprietary technologies. They must continue to innovate and execute effectively to maintain their competitive position.
Major Acquisitions
Athea Vascular
- Year: 2022
- Acquisition Price (USD millions): 18.5
- Strategic Rationale: Athea Vascular strengthens AngioDynamics' existing thrombus management portfolio, including its AlphaVac F188 System.
Growth Trajectory and Initiatives
Historical Growth: Historical growth relies on financial documentation.
Future Projections: Future projections are based on third-party analyst estimates.
Recent Initiatives: Recent initiatives include product development, acquisitions, and strategic partnerships. These should be identified through press releases and investor relations materials.
Summary
AngioDynamics is a niche player in the medical device industry with innovative technologies like NanoKnife. The company is smaller compared to its key competitors but has growth potential through strategic acquisitions and expansion into new markets. The company's reliance on key products and its vulnerability to reimbursement changes remain a concern. AngioDynamics needs to improve scalability and focus on marketing to increase sales across the board.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This information is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data should be verified with the company's official filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AngioDynamics Inc
Exchange NASDAQ | Headquaters Latham, NY, United States | ||
IPO Launch date 2004-05-27 | CEO, President & Director Mr. James C. Clemmer | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 675 | Website https://www.angiodynamics.com |
Full time employees 675 | Website https://www.angiodynamics.com |
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.